EntryPoint Capital’s AnaptysBio ANAB Stock Holding History

EntryPoint Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,390	Closed	-$59.9K	–	621
2024 Q2	$59.9K	Buy	+2,390	New	+$55.6K	0.09%	500

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's ANAB Position: Q3 2024 in Review

EntryPoint Capital sold out of AnaptysBio (ANAB) in Q3 2024, closing a stake of 2,390 shares — an estimated $59.9K sold.

EntryPoint Capital first reported a position in ANAB in Q2 2024 and held it in 1 quarter. The position peaked at $59.9K in Q2 2024. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2024.

EntryPoint Capital reported no remaining AnaptysBio position as of Q3 2024 after selling out during the quarter.
EntryPoint Capital sold 2,390 AnaptysBio shares in Q3 2024, an estimated $59.9K.
EntryPoint Capital first reported a position in AnaptysBio in Q2 2024 and held it in 1 quarter.
EntryPoint Capital's AnaptysBio position peaked at $59.9K in Q2 2024.
160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.